糖基化过程中的变化在癌症发生的早期就出现了，并随着癌症的生长和扩散而发展。特征糖基化标志与肿瘤阶段和合适的治疗选择的相关性是转化医学中的重要问题。肿瘤学家还关注细胞外囊泡作为新的癌症糖标记物的储存库，该标记物可用于癌症诊断/预后。在本综述中，我们回顾了在肿瘤学中使用的糖标记物，并展示了它们的新糖形式，这些糖形式具有改进的临床相关性。我们总结了癌症来源的细胞外囊泡中糖表位的生物学功能的当前知识以及它们在临床实践中的潜在用途。糖组学是癌症诊断的未来吗？可能是，但要与其他组学分析结合使用而不是单独使用。版权所有 © 2023 Elsevier B.V. 发布。

Changes in the glycosylation process appear early in carcinogenesis and evolve with the growth and spread of cancer. The correlation of the characteristic glycosylation signature with the tumor stage and the appropriate therapy choice is an important issue in translational medicine. Oncologists also pay attention to extracellular vesicles as reservoirs of new cancer glycomarkers that can be potent for cancer diagnosis/prognosis. In this review, we recall glycomarkers used in oncology and show their new glycoforms of improved clinical relevance. We summarize current knowledge on the biological functions of glycoepitopes in cancer-derived extracellular vesicles and their potential use in clinical practice. Is glycomics a future of cancer diagnosis? It may be, but in combination with other omics analyses than alone.Copyright © 2023. Published by Elsevier B.V.